• 011-26907444
  • raghava@iiitd.ac.in

Browse result page of AntiTbPdb

The total number entries retrieved from this search are 7
IDNameSequenceN-Terminal ModificationC-Terminal ModificationChemical ModificationLinear/CyclicLengthChiralityNatureSourceOriginSpeciesStrainInhibition ConcentrationIn vitro/ In vivoCell LineIntracellular InhibitionCytotoxicityAnimal ModelEffective Dose in model organismImmune ResponceMechanism of ActionTargetCombination TherapyOther ActivitiesYear of PublicationPubmed ID/ Patent No.
antitb_1018Ecumicin (N,N-Me2-Val)-(Val)-(N-Me-allo-Ilu)-(Thr)-(N-Me-Thr)-(Val)-(N-Me-Leu)-(Val)-(N-Me-Val)-(N-Me-4-OMe-Trp)-(Val)-(Ph-threo-Ser)-(Val)FreeFreeN-methylation pattern, N-Me-Val = N-methyl-valine, N,N-Me2-Val = N,N-dimethyl-valine, N-Me-Thr = N-methyl-threonine, N-Me-Leu = N-methyl-leucine, N-Me-allo-Ilu = N-methyl-isoleucine, N-Me-4-OMe-Trp = N-methyl-4-methoxy-tryptophan, Ph-threo-Ser = PheMacrocyclic13LNANaturalProduced by a genetically distinct Nonomuraea species, strain MJM5123. Mycobacterium kansasiiMycobacterium kansasii (ATCC 12478) MIC = <0.24 μMIn vitroNoneNANANone NoneNAEcumicin markedly enhanced the ATPase activity of wild-type (WT) ClpC1 but prevented activation of proteolysis by ClpC1. so toxic proteins which are normally degraded by the ClpC1P1P2 complex, accumulate in the presence of ecumicinClpC1 ATPase complex NoneNA201525421483
antitb_1146Nisin AI-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANMK-(Abu)-A-(Abu)-ANASIHV-(Dha)-KFreeFreeDha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and AlaCyclic (5 hinge region due to presence of lanthion34LNANaturalProduced by Lactococcus lactis Mycobacterium kansasiiMycobacterium kansasii CIT11/06 NAIn vitroNoneNANANone NANANANANoneAntibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes)201021468208
antitb_1151Nisin VI-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANVK-(Abu)-A-(Abu)-ANASIHV-(Dha)-KFreeFreeDha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and AlaCyclic (5 hinge region dur to presence of lanthion34LNANaturalProduced by Lactococcus lactis Mycobacterium kansasiiMycobacterium kansasii CIT11/06 20% decrease in relative growth as compared to Nicin AIn vitroNoneNANANone NANANANANoneAntibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes)201021468208
antitb_1156Nisin SI-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANMS-(Abu)-A-(Abu)-ANASIHV-(Dha)-KFreeFreeDha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and AlaCyclic (5 hinge region dur to presence of lanthion34LNANaturalProduced by Lactococcus lactis Mycobacterium kansasiiMycobacterium kansasii CIT11/06 Relative growth was reduced by 29% compared to that which occurred in the presence of nisin A.In vitroNoneNANANone NANANANANoneAntibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes)201021468208
antitb_1161Nisin TI-(Dhb)-AI-(Dha)-LA-(Abu)-PGAK-(Abu)-GALMGANMT-(Abu)-A-(Abu)-ANASIHV-(Dha)-KFreeFreeDha= Didehydroalanine, Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid, Lanthionine (Ala-S-Ala) formation from 3-7 Ala, and β-methyllanthionine (Abu-S-Ala) from 8-11, 13-19, 23-26, 25-28 in between Abu and AlaCyclic (5 hinge region dur to presence of lanthion34LNANaturalProduced by Lactococcus lactis Mycobacterium kansasiiMycobacterium kansasii CIT11/06 24% more inhibition as compared to nisin AIn vitroNoneNANANone NANANANANoneAntibacterial (Shigella, Pseudomonas and Salmonella, S. aureus, S. agalactiae and L. monocytogenes)201021468208
antitb_1337Dihydromycoplanecin AR-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3)Propanol is attached FreeR =CH3-CH2-CH(OH)-COCyclic21MixNANaturalAspergillus awajinensisMycobacterium kansasiiMycobacterium kansasiiIC50= 0.39 μg/mL (50%)BothNANANAICR/JCL male mice and male beagle dogs 12 mg/kg for mice and 50mg/kg for dogNANANANANA19883348603
antitb_1340Dihydromycoplanecin AR-N(CH3)-CH(CH-CH3-CH3)-CO-N(CH-C-CH2-CH3-C-CH)-CO-N(CH3)-CH-C)-NH-CH(CH2-CH-CH3-CH3)-CO-N-CH-C-CH3_C-CH)-CONH-CH(CH2-CH2-CH-CH3-CH3)-Co-N-CH3-Ch-CH(CH3-CH3)-Co-N-(CH-C-Ch)-Co-N(CH3)-CH(CH2-CH-CH3-CH3)-CO-NH-CH2-CO-O-CH(CH3)Propanol is attached FreeR =CH3-CH2-CH(OH)-COCyclic21MixNANaturalAspergillus awajinensisMycobacterium kansasiiMycobacterium kansasiiIC90= 0.78 μg/mL(90%)BothNANANAICR/JCL male mice and male beagle dogs 15 mg/kg for mice and 50mg/kg for dogNANANANANA19883348603